Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris

Henseler, Tilo; Christophers, Enno

doi:10.1016/s0190-9622(85)70188-0

Cited by 859 publications

(742 citation statements)

References 15 publications

Supporting

Mentioning

631

Contrasting

Unclassified

Order By: Relevance

“…Patients were considered to have familial psoriasis if they had at least one first-or seconddegree relative with psoriasis, and considered to have sporadic disease if they had no relatives with psoriasis. 55 The severity of psoriasis was quantified by the PASI. 56 The PASI scores were calculated on the basis of the degree of erythema, desquamation and infiltration of lesions combined with the surface extension.…”

Section: Methodsmentioning

confidence: 99%

Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis

et al. 2005

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis

et al. 2005

View full text Add to dashboard Cite

“…Psoriasis was defined by the presence of at least two characteristic skin lesions, 25 or by a single lesion occupying greater than 1% of the total body surface area. Ascertainment was for juvenile onset psoriasis in the proband (i.e., age at onset 440 years 26 ). No age of onset criterion was applied to other family members.…”

Section: Methodsmentioning

confidence: 99%

Combined segregation and linkage analysis of HLA markers in familial psoriasis

et al. 2002

Self Cite

View full text Add to dashboard Cite

“…5,6 Alguns estudos populacionais mostraram que a incidência da psoríase está aumentada em familiares de primeiro e segundo grau e em gémeos monozigóticos, em que atinge concordância de 70%, realçando a base genética na etiologia da doença.…”

Section: -3unclassified

Interleucina-17 como Alvo Terapêutico na Psoríase

Torres

Filipe

2014

Acta Med Port

View full text Add to dashboard Cite

RESUMOA psoríase é uma doença crónica, inflamatória, imunomediada que afecta cerca de 1-3% da população geral. O avanço no conhecimento da patogénese da psoríase levou ao desenvolvimento de novos fármacos direccionados para vias imunitárias mais específicas que os existentes. A IL-17 e os linfócitos Th17 têm um importante papel na patogénese de várias doenças auto-imunes e imunomediadas, incluindo a psoríase. A IL-17A é uma citocina pró-inflamatória, produzida pelos linfócitos Th17 juntamente com outras citocinas efetoras, como a IL-17F e IL-22. Esta citocina é igualmente expressa por outras células do sistema imune inato, incluíndo os mastócitos, neutrófilos e células dendríticas, todas elas encontradas nas lesões de psoríase. Por esta razão a IL-17 surgiu como um alvo terapêutico potencial. Vários agentes que inibem a IL-17 estão em desenvolvimento e os resultados clínicos preliminares são bastante promissores, confirmando a importância da IL-17 na fisiopatologia da psoríase. A intervenção selectiva no sistema imune desta nova classe de agentes biotecnológicos, torna-os uma abordagem terapêutica interessante no controlo de doenças auto-imunes e imunomediadas, como na psoríase. Num futuro próximo, estas novas terapêuticas poderão constituir uma alternativa válida aos agentes biológicos actualmente disponíveis. Palavras-chave: Anticorpos Monoclonais; Psoríase; Interleucina-17; Secukinumab; Ixekizumab; Brodalumab; Portugal. ABSTRACTPsoriasis is a chronic, immune-mediated inflammatory disease that affects up to 1-3% of the general population. An advanced understanding of the immune-pathogenesis of psoriasis has led to the development of new drugs that refine existing treatments or target novel molecular and immunologic pathways. IL-17 and Th17 cells play an important role in the pathogenesis of several autoimmune and immune-mediated disorders, including psoriasis. IL-17A, a pro-inflammatory cytokine, is produced by Th17 cells along with other effector cytokines, such as IL-17F an IL-22, but it is also expressed by other cells of the innate immune system, including mast cells, neutrophils or dendritic cells, that are found in psoriatic lesions. For this reason IL-17 has emerged as an attractive therapeutic target. Agents that inhibit IL-17 are in development and preliminary clinical results are promising, confirming the importance of IL-17 in psoriasis pathophysiology. Their selective intervention in the immune system makes them an attractive therapeutic approach to autoimmune diseases, particularly psoriasis, being possible that in the near future these novel therapies could be a valid alternative for currently available biologic agents. Keywords: Antibodies, Monoclonal; Psoriasis; Interleukine-17; Secukinumab; Ixekizumab; Brodalumab; Portugal. INTRODUÇÃOA psoríase é uma patologia relevante na prática clínica quer pela sua frequência quer pelo seu quadro clínico, que varia desde uma doença cutânea ligeira a uma doença multissistémica, grave e incapacitante.É uma doença crónica, inflamatória, imunomediada, com uma ...

show abstract

Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris

Cited by 859 publications

References 15 publications

Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis

Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis

Combined segregation and linkage analysis of HLA markers in familial psoriasis

Interleucina-17 como Alvo Terapêutico na Psoríase

Contact Info

Product

Resources

About